In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours
暂无分享,去创建一个
J. Bilello | G. Drusano | W. Symonds | D. Stein | P. Piliero | S. Preston
[1] G. Drusano,et al. Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation , 2002, Antimicrobial Agents and Chemotherapy.
[2] B. Sadler,et al. Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir , 2002, Antimicrobial Agents and Chemotherapy.
[3] Susan Swindells,et al. Erratum: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (Annals of Internal Medicine (2000) 133 (21-30)) , 2002 .
[4] Joseph Quinn,et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.
[5] B. Sadler,et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers , 2001, AIDS.
[6] J. Bilello,et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. , 2001, The Journal of infectious diseases.
[7] D. Back,et al. Principles and practice of HIV‐protease inhibitor pharmacoenhancement , 2001, HIV medicine.
[8] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[9] R. Hogg,et al. Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy? , 1998, The Journal of infectious diseases.
[10] J. Bilello,et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. , 1998, The Journal of infectious diseases.
[11] J. Leonard,et al. The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir , 1998, AIDS.
[12] J. Leonard,et al. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro , 1995, Antimicrobial agents and chemotherapy.
[13] J A Bilello,et al. Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies , 1994, Antimicrobial Agents and Chemotherapy.
[14] J. Bilello,et al. Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease , 1993, Antimicrobial Agents and Chemotherapy.